WO2018132160A3 - Methods of treating or preventing type 1 diabetes - Google Patents

Methods of treating or preventing type 1 diabetes Download PDF

Info

Publication number
WO2018132160A3
WO2018132160A3 PCT/US2017/059987 US2017059987W WO2018132160A3 WO 2018132160 A3 WO2018132160 A3 WO 2018132160A3 US 2017059987 W US2017059987 W US 2017059987W WO 2018132160 A3 WO2018132160 A3 WO 2018132160A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
methods
treating
preventing type
subject
Prior art date
Application number
PCT/US2017/059987
Other languages
French (fr)
Other versions
WO2018132160A2 (en
Inventor
Christophe Benoist
Diane Mathis
Tze Guan TAN
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2018132160A2 publication Critical patent/WO2018132160A2/en
Publication of WO2018132160A3 publication Critical patent/WO2018132160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464421—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are methods and compositions related to the treatment and/or prevention of type 1 diabetes in a subject by administering to the subject CXCR3+ regulatory T cells or an agent that increases the frequency or activity of CXCR3+ regulatory T cells in the subject.
PCT/US2017/059987 2016-11-03 2017-11-03 Methods of treating or preventing type 1 diabetes WO2018132160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417118P 2016-11-03 2016-11-03
US62/417,118 2016-11-03

Publications (2)

Publication Number Publication Date
WO2018132160A2 WO2018132160A2 (en) 2018-07-19
WO2018132160A3 true WO2018132160A3 (en) 2018-10-25

Family

ID=62567719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/059987 WO2018132160A2 (en) 2016-11-03 2017-11-03 Methods of treating or preventing type 1 diabetes

Country Status (1)

Country Link
WO (1) WO2018132160A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066619A1 (en) * 2001-02-16 2002-08-29 The Wistar Institute Of Anatomy And Biology Methods of treating inflammation, particularly diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066619A1 (en) * 2001-02-16 2002-08-29 The Wistar Institute Of Anatomy And Biology Methods of treating inflammation, particularly diabetes

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLUESTONE J A ET AL: "Type 1 diabetes immunotherapy using polyclonal regulatory T cells", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 315, 315RA189, 25 November 2015 (2015-11-25), XP055378042, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aad4134 *
CABELLO-KINDELAN C ET AL: "Adoptive T Regulatory Cell Therapy for Tolerance Induction", CURRENT TRANSPLANTATION REPORTS, vol. 2, no. 2, 2 April 2015 (2015-04-02), pages 191 - 201, XP055504152, DOI: 10.1007/s40472-015-0058-5 *
FRIGERIO S ET AL: "Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis", NATURE MEDICINE, vol. 8, no. 12, 4 November 2002 (2002-11-04), pages 1414 - 1420, XP055152746, ISSN: 1078-8956, DOI: 10.1038/nm1202-792 *
KOCH M A ET AL: "The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation", NATURE IMMUNOLOGY, vol. 10, no. 6, 3 May 2009 (2009-05-03), pages 595 - 602, XP055504356, ISSN: 1529-2908, DOI: 10.1038/ni.1731 *
KORNETE M ET AL: "Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to [beta]-Islets during Pre-Diabetes in BDC2.5 NOD Mice", PLOS ONE, vol. 10, no. 5, E0126311, 6 May 2015 (2015-05-06), XP055504352, DOI: 10.1371/journal.pone.0126311 *
MAREK-TRZONKOWSKA N ET AL: "Administration of CD4+CD25highCD127- Regulatory T Cells Preserves Beta-Cell Function in Type 1 Diabetes in Children", DIABETES CARE, vol. 35, no. 9, 20 June 2012 (2012-06-20), pages 1817 - 1820, XP055083620, ISSN: 0149-5992, DOI: 10.2337/dc12-0038 *
MAREK-TRZONKOWSKA N ET AL: "Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets - Results of one year follo", CLINICAL IMMUNOLOGY, vol. 153, no. 1, 1 April 2014 (2014-04-01), pages 23 - 30, XP029006131, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2014.03.016 *
MING J ET AL: "Peptide Nucleic Acid Antisense Prolongs Skin Allograft Survival by Means of Blockade of CXCR3 Expression Directing T Cells into Graft", THE JOURNAL OF IMMUNOLOGY, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1556 - 1565, XP055504155, ISSN: 0022-1767, DOI: 10.4049/jimmunol.170.3.1556 *
TAN T G ET AL: "Singular role for T-BET + CXCR3 + regulatory T cells in protection from autoimmune diabetes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 49, 21 November 2016 (2016-11-21), pages 14103 - 14108, XP055504150, ISSN: 0027-8424, DOI: 10.1073/pnas.1616710113 *
YAMADA Y ET AL: "Acceleration of diabetes development in CXC chemokine receptor 3 (CXCR3)-deficient NOD mice", DIABETOLOGIA, vol. 55, no. 8, 11 April 2012 (2012-04-11), pages 2238 - 2245, XP035081583, ISSN: 1432-0428, DOI: 10.1007/S00125-012-2547-8 *

Also Published As

Publication number Publication date
WO2018132160A2 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CY1122603T1 (en) GAMMA-DIKETONES FOR THE THERAPEUTIC TREATMENT AND PREVENTION OF SKIN AGING AND WRINKLES
WO2018022668A3 (en) Neuromodulating compositions and related therapeutic methods for the treatment of cancer
MX2021004821A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2022001165A (en) Therapeutic compositions, combinations, and methods of use.
MA40437A (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MY194586A (en) Anti-garp antibody
WO2019006005A3 (en) Methods and compositions for treating melanoma
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12019501010A1 (en) Arginase inhibitor combination therapies
EP4223297A3 (en) Administration and dosage of diaminophenothiazines
MX2015016100A (en) Cryopyrin inhibitors for preventing and treating inflammation.
MX2017005134A (en) Treatment of cancer with immune stimulators.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
MX365366B (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
MX2019015676A (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug.
MX2020011817A (en) Methods for treating lymphoma.
MX2019013862A (en) Combination therapy.
TW201613592A (en) Glucose metabolism ameliorating agent
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17879662

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17879662

Country of ref document: EP

Kind code of ref document: A2